Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer

NCT07368543 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

216

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Sacituzumab Govitecan
DRUG: Trastuzumab Deruxtecan

Sponsor

Fudan University